Symposium Co-Chairs
Roy S. Herbst, MD, PhD
Professor of Medicine
Chief, Section of Thoracic Medical Oncology
Department of Thoracic/Head and Neck Medical Oncology
Barnhart Family Distinguished Professor in Targeted Therapies
The University of Texas M. D. Anderson Cancer Center
Houston, TX
Rafael Rosell, MD, PhD
Chief, Medical Oncology Service
Scientific Director of Oncology Research
Catalan Institute of Oncology
Hospital Germans Trias I Pujol
Barcelona, Spain
Vincent A. Miller, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, NY
Jyoti D. Patel, MD
Assistant Professor
Division of Hematology/Oncology
Robert H. Lurie Comprehensive Cancer Center
Chicago, IL
Alan B. Sandler, MD
Professor of Medicine
Division Chief, Hematology & Medical Oncology
DeArmond Chair, Clinical Cancer Research
Oregon Health & Science University
Portland, OR
Co-Chair, Lung Committee, Eastern Cooperative Oncology Group (ECOG)
|
|
Emerging Novel Strategies for Personalized Initial and Maintenance Therapy of NSCLC: Critical Questions Addressed by the Experts
|
|
PLEASE NOTE:
Pre-registration is now available on a "stand-by" basis only. We have received the maximum number of 400 confirmed pre-registrants. We do expect that approximately 50 pre-registrants will not attend. So if you are interested in attending this symposium please register now as a "stand-by" pre-registrant. At 6:30PM on June 5, 2010 "standy-by" registrants can attend the symposium on a first-come basis. Thank you.
June 5, 2010 | Chicago IL
Hyatt Regency McCormick Place
Conference Center Rooms 10-A, B, C, D
2233 South Martin Luther King Drive
Chicago, IL 60616
6 PM - 6:30PM Registration and Dinner
6:30PM - 8:30PM CME Symposium
Taught by the top academic experts in NSCLC this is THE symposium on NSCLC that you should attend in 2010.
|
|
|
CO-CHAIRS
Roy S. Herbst, MD, PhD
Professor of Medicine
Chief, Section of Thoracic Medical Oncology
Department of Thoracic/Head and Neck Medical Oncology
Barnhart Family Distinguished Professor in Targeted Therapies
The University of Texas M. D. Anderson Cancer Center
Houston, TX
Rafael Rosell, MD, PhD
Chief, Medical Oncology Service
Scientific Director of Oncology Research
Catalan Institute of Oncology
Hospital Germans Trias I Pujol
Barcelona, Spain
|
|
|
|
|
|
| June 5, 2010 – Saturday |
| 6:00PM - 6:30PM |
Registration and Reception |
| 6:30PM |
Welcome and Introductions and CME Pre Test |
Roy S. Herbst, MD, PhD |
| 6:35PM |
Will combining anti-EGFR inhibition with anti-angiogenesis inhibition for NSCLC maintenance therapy improve overall survival? |
Vincent A. Miller, MD |
| 6:50PM |
Interactive Roundtable Discussion
|
Faculty |
| 7:00PM |
Will initial and maintenance therapy with oral anti-EGFR inhibition become the new standard for EGFR mutation-positive NSCLC? |
Rafael Rosell, MD, PhD |
| 7:20PM |
Interactive Roundtable Discussion
|
Faculty |
| 7:30PM |
Will initial and maintenance therapy with bevacizumab for become a standard option for nonsquamous NSCLC?
|
Alan B. Sandler, MD |
| 7:50PM |
Interactive Roundtable Discussion |
Faculty |
| 8:00PM |
Will anti-angiogenesis inhibition become an essential therapy component with chemotherapy for initial and maintenance therapy for nonsquamous NSCLC? |
Jyoti D. Patel, MD |
| 8:15PM |
Interactive Roundtable Discussion and Q & A |
Faculty |
| 8:25PM |
Closing remarks and post-activity clinical treatment strategy assessment questions utilizing interactive ARS |
Roy S. Herbst, MD, PhD |
| 8:30PM |
AJOURN |
|
|
|
| Educational Grants |
Sincere appreciation is extended to Genentech for their generous commercial support of this educational meeting. |
|
|
|
